文献速递其他结缔组织病类风湿关节炎

磷酸二酯酶-4抑制作为风湿性疾病相关间质性肺疾病治疗策略的依据

Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases.
PubMed 文献 · RMD Open · 2024-12-23

本文综述临床前与临床数据,阐述磷酸二酯酶4(PDE4)尤其PDE4B亚型抑制作为系统性自身免疫风湿病相关间质性肺疾病(SARD-ILD)治疗策略的依据。SARD-ILD致病与死亡负担重,亟需同时靶向纤维化与炎症通路的有效疗法。在特发性肺纤维化(IPF)的II期概念验证试验中,PDE4B抑制剂奈兰多司特(BI 1015550)与安慰剂相比可防止12周内肺功能下降。

要点

  • SARD-ILD致病与死亡负担重,亟需同时靶向纤维化与炎症通路的有效疗法。
  • PDE4B抑制的临床前数据初步显示抗炎与抗纤维化活性,胃肠道毒性潜力低于泛PDE4抑制剂。
  • IPF的II期概念验证试验中,奈兰多司特与安慰剂相比防止12周内肺功能下降。

核心结论

  • PDE4B抑制的临床前与临床数据为将其作为SARD-ILD治疗策略提供了依据,PDE4B抑制可能是纤维化性ILD(如IPF与SARD-ILD)的新方法。

研究设计与样本

  • 本综述汇总PDE4B抑制的临床前与临床数据,以阐述其在SARD-ILD治疗中的依据。

主要发现

  • PDE4水解环磷酸腺苷(cyclic AMP),后者调节炎症过程的多个通路,PDE4在炎症疾病患者外周血单核细胞中过表达。
  • 纤维化疾病中泛PDE4抑制的临床数据缺乏;PDE4B亚型在大脑、肺、心脏、骨骼肌和免疫细胞中高表达。
  • PDE4B抑制的临床前数据初步显示抗炎与抗纤维化活性,与泛PDE4抑制剂相比胃肠道毒性潜力降低。
  • 在IPF的II期概念验证试验中,奈兰多司特(BI 1015550)与安慰剂相比防止了12周内肺功能下降。
  • PDE4B抑制的潜在临床获益正在III期研究中评估,两项试验分别在IPF(FIBRONEER-IPF)与除IPF外的进展性肺纤维化(FIBRONEER-ILD)患者中评价奈兰多司特。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Interstitial lung disease (ILD) associated with rheumatoid arthritis or with connective tissue diseases such as systemic sclerosis can be collectively named systemic autoimmune rheumatic disease-associated ILDs (SARD-ILDs) or rheumatic musculoskeletal disorder-associated ILDs. SARD-ILDs result in substantial morbidity and mortality, and there is a high medical need for effective therapies that target both fibrotic and inflammatory pathways in SARD-ILD. Phosphodiesterase 4 (PDE4) hydrolyses cyclic AMP, which regulates multiple pathways involved in inflammatory processes. PDE4 is overexpressed in peripheral blood monocytes from patients with inflammatory diseases. However, clinical data on pan-PDE4 inhibition in fibrotic conditions are lacking. The PDE4B subtype is highly expressed in the brain, lungs, heart, skeletal muscle and immune cells. As such, inhibition of PDE4B may be a novel approach for fibrosing ILDs such as idiopathic pulmonary fibrosis (IPF) and SARD-ILD. Preclinical data for PDE4B inhibition have provided initial evidence of both anti-inflammatory and antifibrotic activity, with reduced potential for gastrointestinal toxicity compared with pan-PDE4 inhibitors. In a proof-of-concept phase II trial in patients with IPF, nerandomilast (BI 1015550), the only PDE4B inhibitor currently in clinical development, prevented a decline in lung function over 12 weeks compared with placebo. The potential clinical benefit of PDE4B inhibition is now being investigated in the phase III setting, with two trials evaluating nerandomilast in patients with IPF (FIBRONEER-IPF) or with progressive pulmonary fibrosis other than IPF (FIBRONEER-ILD). Here, we review the preclinical and clinical data that provide rationale for PDE4B inhibition as a treatment strategy in patients with SARD-ILD.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Aringer M, Distler O, Hoffmann-Vold AM, et al. Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases. RMD Open. 2024. PMID: 39719300. doi:10.1136/rmdopen-2024-004704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。